Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Affymetrix's market focus

Affymetrix Inc., (Santa Clara, Calif.) leader of a consortium that last week was awarded a $31.5 million government grant to develop miniaturized DNA diagnostic systems, will focus on building high-tech tools for biomedical research and leave the development of clinical applications to its customers.

Affymetrix, a subsidiary of Affymax N.V. (AFMXF), uses photolithographic techniques and solid phase chemical synthesis to create arrays of DNA

Read the full 630 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers